Multinational clinical trials generate large volumes of documentation that must be translated before regulatory authorities will review a trial authorisation application. The quality of that translation is a regulatory requirement, and the consequences of getting it wrong range from delayed approvals to requests for full document re-submission.
What GCP documentation requires translation
Every clinical trial operating across multiple countries needs translated documentation for regulatory submission, ethics committee approval, and site operations. The scope is broader than many sponsors anticipate at the planning stage.
Documents routinely requiring translation include:
- Clinical trial protocol and all subsequent amendments
- Investigator's Brochure (IB) and annual updates
- Informed Consent Form (ICF) and all participant-facing materials
- Site operations manual and standard operating procedures (SOPs)
- Safety notifications (SUSARs, DSURs, expedited safety reports)
- Patient-Reported Outcome (PRO) instruments and questionnaires
- Investigator and site staff training materials
Each document type carries its own regulatory and formatting requirements. The ICF in particular is subject to ethics committee approval in every participating country and must faithfully represent the scope of participant consent in the local language.
Regulatory requirements across European markets
EU Regulation 536/2014 on clinical trials of medicinal products for human use requires that documentation accessible to participants be provided in the official language or languages of the Member State concerned. The CTIS platform, through which trial authorisation applications are submitted to the EMA and national competent authorities, reflects this requirement in its submission structure.
National authorities add their own requirements on top of the EU framework. In Portugal, the INFARMED generally accepts English for scientific and technical documentation directed at investigators, but requires European Portuguese for all participant-facing materials. This distinction matters: a Brazilian Portuguese translation is not accepted for submissions in Portugal. Similar distinctions apply in Spain (Castilian versus regional co-official languages in certain autonomous communities) and France (which has strict requirements for French-language participant materials under national law).
Translating clinical trial protocols for regulatory submission is a well-defined process, but the national variations mean that a single translation workflow rarely covers all markets without country-specific adaptation.
For sponsors managing trials across five or more countries, inconsistencies between language versions of the protocol or ICF are one of the most common causes of questions from competent authorities during the assessment period. A discrepancy between the French and German versions of a primary endpoint definition, for example, will generate a clarification request that delays the authorisation clock.
Terminology management and version control
Terminology consistency is where clinical trial translation workflows most frequently break down. The same concept described differently across documents in the same submission creates problems that reviewers will find.
A controlled translation process for GCP documentation requires:
- Trial-specific glossary: built before translation begins, covering the IMP name, inclusion and exclusion criteria, primary and secondary endpoints, and key procedural terms
- Translation memories: ensure that identical or near-identical text across the protocol, amendments, and IB updates is rendered consistently
- Therapeutic area review: a translator or reviewer with domain expertise in the relevant field (oncology, neurology, cardiology) validates that clinical terminology is used correctly in context
- Version tracking: every translated document must identify the source version, version date, and version number it corresponds to
ISO 17100:2015 sets the process requirements for professional translation services, including mandatory qualifications for translators and reviewers. Working with an ISO 17100-certified provider gives sponsors documented evidence of process quality, which can be relevant in the event of a regulatory audit of the trial master file.
The documentation standards applied to medical device translation under the MDR follow similar traceability logic, and many sponsors working across both pharmaceutical and device programmes benefit from a unified quality approach.
Participant materials: accuracy and readability together
The Informed Consent Form sits at the intersection of legal, clinical, and plain-language requirements. The translation must be precise enough to satisfy the ethics committee and accessible enough for a participant with no medical background to understand their rights and the risks involved.
This is not a theoretical tension. Ethics committees in most European countries assess whether the translated ICF accurately represents the original, and whether the language is appropriate for the intended participant population. An overly technical translation will be sent back for revision. So will one that has simplified the risks to the point of misrepresentation.
PRO instruments add a further layer of complexity. When a validated instrument is adapted for use in a clinical trial in a new language, the process must follow a defined linguistic validation methodology: forward translation, back-translation, reconciliation, and cognitive debriefing with native-speaking participants. This is not standard document translation. It is a documented methodological process that generates evidence of equivalence between the original and the adapted version.
Working with M21Global on clinical trial documentation
M21Global provides pharmaceutical translation services certified to ISO 17100:2015 and ISO 18587, covering the full range of GCP documentation for clinical trial submissions. The team includes translators with specialisation in clinical and regulatory documentation across therapeutic areas, with centralised terminology and version management for multinational programmes.
For sponsors and CROs running trials with sites in Portugal, Spain, France, Germany, and Portuguese-speaking markets including Angola and Brazil, M21Global manages linguistic consistency across all submission versions from a single point of contact. Regulatory timelines do not accommodate rework caused by terminological inconsistencies between language versions.
Request a quote for your GCP documentation translation at m21global.com/en/services/pharmaceutical-translation, or contact the pharmaceutical projects team directly to discuss your trial's specific requirements.
Related Services
Request a free medical translation quote
- Request a free medical translation quote
- Medical Device Documentation Translation Mdr Compliance
- Translating Clinical Trial Protocols Regulatory Submission
- Drug Labeling Translation
Frequently Asked Questions
Does the Informed Consent Form need to be translated for every country in a multinational trial?
Yes. EU Regulation 536/2014 requires participant-facing materials to be in the official language of each participating Member State. Ethics committees in each country will review the translated ICF before granting approval.
What is the difference between standard document translation and PRO linguistic validation?
Standard translation transfers meaning from one language to another. PRO linguistic validation for a validated instrument follows a defined methodology including forward translation, back-translation, reconciliation, and cognitive debriefing to demonstrate equivalence between the original and the adapted version.
Is ISO 17100 certification required for clinical trial document translation?
It is not universally mandatory, but it provides documented evidence of process quality that can be relevant during a regulatory audit of the trial master file. ISO 17100-certified providers operate under audited processes with defined qualifications for translators and reviewers.
Can the same translation be used for Portugal and Brazil?
No. The INFARMED requires European Portuguese for participant-facing materials submitted in Portugal. A Brazilian Portuguese translation is not accepted. The same principle applies in other markets where regional language variants exist.
How do sponsors manage terminology consistency across multiple language versions of a protocol?
The standard approach is to build a trial-specific glossary before translation begins and use translation memories throughout the project. This ensures that key terms, endpoint definitions, and procedural descriptions are rendered identically across all language versions and all document updates.
